CCORF Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $49
Atricure's Market Strength and Innovation Justify Buy Rating
Oppenheimer Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $32
Navigating 6 Analyst Ratings For AtriCure
AtriCure Price Target Cut to $53.00/Share From $58.00 by BTIG
JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $30
A Quick Look at Today's Ratings for AtriCure(ATRC.US), With a Forecast Between $26 to $60
Needham Maintains Buy on AtriCure, Lowers Price Target to $34
AtriCure Price Target Cut to $40.00/Share From $65.00 by Piper Sandler
AtriCure Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Incyte (INCY), Atricure (ATRC)
Piper Sandler Remains a Buy on Atricure (ATRC)
Atricure's Stable Financials and Strategic Growth Outlook Justify Buy Rating
AtriCure's Growth Prospects and Buy Rating Despite Short-Term Challenges
Analyst Ratings For AtriCure
AtriCure Analyst Ratings
Needham Reiterates Buy on AtriCure, Maintains $40 Price Target
Atricure's Competitive Landscape Clears: A Buy Rating Amid Delayed Threats and Growth Prospects
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Immunovant (IMVT) and Monte Rosa Therapeutics (GLUE)
Komo: Maintaining the AtriCure (ATRC.US) rating, adjusted from an increase in holdings to an increase in holdings rating, and the target price was adjusted from $42.00 to $34.00.